Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Dyne Therapeutics (Nasdaq: DYN) announced that CEO Joshua Brumm will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA. The presentation will be available via live webcast on Dyne's website, with a replay accessible for 30 days afterward. Dyne focuses on developing innovative therapeutics for genetically driven muscle diseases using its FORCE™ platform, targeting conditions like myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.

WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief executive officer, is scheduled to present at the 41^st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 10, 2023 at 3:00 p.m. PT (6:00 p.m. ET).

A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 30 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

When will Dyne Therapeutics present at the J.P. Morgan Healthcare Conference?

Dyne Therapeutics will present on January 10, 2023, at 3:00 p.m. PT (6:00 p.m. ET).

Where can I watch Dyne Therapeutics' presentation live?

The presentation will be available via live webcast on Dyne's Investor & Media webpage.

What is Dyne Therapeutics focused on?

Dyne Therapeutics is focused on advancing therapeutics for genetically driven muscle diseases.

What platform does Dyne Therapeutics use to develop its therapies?

Dyne uses its proprietary FORCE™ platform to develop modern oligonucleotide therapeutics.

What diseases are targeted by Dyne Therapeutics' programs?

Dyne Therapeutics is developing programs for myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.